Ixmyelocel-T
Sponsors
Vericel Corporation, University of Michigan
Conditions
Cleft PalateCritical Limb IschemiaDilated CardiomyopathyIschemic Dilated Cardiomyopathy (IDCM)OsteonecrosisPeripheral Arterial DiseaseTrauma
Phase 1
Phase 2
Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
CompletedNCT00468000
Start: 2007-04-30End: 2011-03-31Updated: 2020-05-20
Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
CompletedNCT00765518
Start: 2008-09-30End: 2012-09-05Updated: 2021-05-27
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
CompletedNCT01020968
Start: 2009-12-31End: 2013-12-05Updated: 2021-05-27
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
CompletedNCT01670981
Start: 2013-02-20End: 2018-03-07Updated: 2021-05-27
Phase 3
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
CompletedNCT00505219
Start: 2007-09-30End: 2010-12-31Updated: 2019-10-21
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
CompletedNCT01483898
Start: 2012-02-29End: 2014-03-25Updated: 2021-05-27